Drug

Sevoflurane

As of the edition of 20 October 2026, Sevoflurane is a small molecule: marketed, first approved in 1995 (US); acts on GLRA1, KCNK10 and KCNK18 and 3 more; no US protection is listed.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 1997
Kind
Small molecule
Brand name
Ultane
First approved
7 June 1995 (US)
Approvals on record
7 in 5 regions
Holder of the most recent approval
Baxter Healthcare; 2 holders in all
Registered trials
293, 20 stopped early
Disease areas
Nervous system; Heart and blood vessels; Mental health; Cancer; Lungs and airways; Urinary and reproductive

US protection

No US protection is listed.

The FDA registers list no drug-substance patent or exclusivity that counts for this drug.

This is the US only.

Companies that need a new molecule because of this drug

12 company-target rows on route B because of this drug.

Companies on route B for this drug

In the product

12 company-target rows are on route B because of Sevoflurane.

Targets

GeneProteinUniProt
KCNK3Potassium channel subfamily K member 3O14649
KCNK2Potassium channel subfamily K member 2O95069
GLRA1Glycine receptor subunit alpha-1P23415
KCNK10Potassium channel subfamily K member 10P57789
KCNK18Potassium channel subfamily K member 18Q7Z418
KCNK9Potassium channel subfamily K member 9Q9NPC2

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase not stated155981610
Phase 1131010
Phase 2181413
Phase 3241711
Phase 4834666
All trials293

Who has held its approvals

CompanyRoleYears
Baxter HealthcareApplicant2005 to now
AbbVieAcquired holder2012 to now
AbbottOriginator1995 to 2012